Cambrex Sells In Vitro Diagnostic Product Line

01.03.2002

East Rutherford, NJ - February 28, 2002 - Cambrex Corporation announced today the sale of the in vitro diagnostic product line of BioWhittaker, Inc., a subsidiary of Cambrex Corporation, to Diagnostic Hybrids, Inc. Sales revenue from this product line was $4.3 million in 2001. The divestiture will permit Cambrex to better focus resources on strategic, higher growth businesses, such as its Clonetics® and Poietics® human cells and cell culture products for research and therapeutic applications.

The terms of sale include first-year payments of approximately $1.1 million and the potential for an additional $1.4 million based on product line performance. Under separate one-year agreements, BioWhittaker will continue to manufacture the standard tube diagnostic products and provide sales, marketing and administrative support to assure a smooth transition.

Cambrex is a global, diversified life science company dedicated to providing high quality products and services to accelerate drug discovery, development, and manufacturing processes for our pharmaceutical, biopharmaceutical, biotechnology, and research customers. With approximately 2000 employees worldwide, Cambrex provides pharmaceutical outsourcing services, from grams to tons, to ethical and generic drug companies using both biological and chemical platforms.

Various statements made in this press release may constitute "forward-looking" statements for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act and Rule 3B-6 under The Exchange Act. The forward-looking statements may be indicated through use of the words "intend," "may," "expected," "plan," and other words of similar meaning. The forward-looking statements contained herein may involve technological and competitive risks and uncertainties that exist in the Company's operations and business environment that may cause results to differ materially from the Company's expectations. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to factors detailed in Cambrex's Annual Report on Form-10K and other filings with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update or revise any forward-looking statements.

https://www.bionity.com/de/news/8968/cambrex-sells-in-vitro-diagnostic-product-line.html